Therapeutic binding molecules

Details Therapeutic binding molecules Therapeutic binding molecules

2005-12-08

2010-11-02

Szperka, Michael (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388150, C530S387300, C424S130100

Reexamination Certificate

active

07825222

ABSTRACT:
A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

REFERENCES:
patent: 5759808 (1998-06-01), Casterman et al.
patent: 98/11918 (1998-03-01), None
patent: WO 02/072832 (2002-09-01), None
Janeway et al. Immunobiology, 3rdEd. Garland Press, 1997, p. 3:7-3:11.
Fundamental Immunology, William E. Paul, MD 3rded. 1993, p. 242.
Portolano et al., J. Immunology, 1993, vol. 150. p. 880-887.
Aversa et al., “Use of Monoclonal Antibodies to Study in vivo and in vitro Activated Lymphocytes”, Transplantation Proceedings, vol. 21, No. 1, part 1, pp. 349-350 (1989).
Aversa et al., “A Monoclonal Antibodi (A6) Recognizing a Unique Epitope Restricted to CD45RO and—RB Isoforms of the Leukocyte Common Antigen Family Identifies Functional T Cell Subsets”, Cellular Immunology, vol. 158, No. 2, pp. 314-328 (1994).
Kolbinger et al., “Humanization of a Mouse Anti-Human IgE Antibody: A Potential Therapeutic for IgE-Mediated Allergies”, Protein Engineering, vol. 6, No. 8, pp. 971-980 (1993).
Petersen et al., “Autoreactive and immunoregulatory T-Cell Subsets in Insulin-Dependent Diabetes Mellitus”, Diabetologia, vol. 42, pp. 443-449 (1999).
Trowbridge et al., “NL6 CD45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and Development”, Annu. Rev. Immunol., vol. 12, pp. 85-116 (1994).
Sewell et al., “CD45 Workshop Panel Report”, Proc 6thIntern Workshop and Conference held in Kobe, JP, Nov. 10-14, 1996, pp. 499-505 (1996).
Aversa et al., “Cell Surface Markers of T-Cell Activation”, Transplantation Reviews, vol. 5, No. 1, pp. 9-30 (1991).
Morimoto et al., “T18 CD45 Cluster Report”, Proc 5thIntern Workshop and Conference held in Boston, US, Nov. 3-7, 1993, pp. 386-398 (1993).
Sasaki et al., “New Insights into the Transmembrane Protein Tyrosine Phosphatase CD45”, Intern. J. Biochem. & Cell Biol., vol. 33, pp. 1041-1046 (2001).
Dunn-Walters et al., “Effect of Somatic Hypermutation on Potential N-glycosylation Sites in Human Immunoglobulin Heavy Chain Vaiable Regions”, Molecular Immunology, 2000 vol. 37 pp. 107-113.
Friend et al., “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection”, Transplantation, 1999 vol. 68 No. 11 pp. 1632-1637.
Gregori et al., “Anti-CD45RO/RB mAb a New Tool for Tolerance Induction”, The FASEB Journal, 2003 vol. 17 No. 7 p. C63.

Affiliated with

Also associated with

Rating

Therapeutic binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic binding molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4228909